Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2453 December 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:		
Reg No:	First Names:	First Names:		
Name:	Surname:	Surname:		
Address:	DOB:	Address:		
	Address:			
Fax Number:		Fax Number:		
Bevacizumab				
Initial application — unresectable hepatocellular carcinoma Applications from any relevant practitioner. Approvals valid for 6 months.  Prerequisites(tick boxes where appropriate)  Patient is currently on treatment with bevacizumab, and met all remaining criteria prior to commencing treatment  or  Patient has locally advanced or metastatic, unresectable hepatocellular carcinoma  And Patient has preserved liver function (Child-Pugh A)  and Transarterial chemoembolisation (TACE) is unsuitable  and Patient has not received prior systemic therapy for the treatment of hepatocellular carcinoma  or Patient received funded lenvatinib before 1 March 2025  or Patient has experienced treatment-limiting toxicity from treatment with lenvatinib  and No disease progression since initiation of lenvatinib  and To be given in combination with atezolizumab				
Current approval Number (if known):  Applications from any relevant practitioner. Approv  Prerequisites(tick box where appropriate)				
There is no evidence of disease progression				

I confirm the above details are correct and that in signing this form I understand I may be audited.

Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 2 Form SA2453 December 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:			
Reg No:	First Names:	First Names:			
Name:	Surname:	Surname:			
Address:	DOB:	Address:			
	Address:				
Fax Number:		Fax Number:			
Bevacizumab - continued					
Initial application — advanced or metastatic ovarian cancer Applications from any relevant practitioner. Approvals valid for 4 months.  Prerequisites(tick boxes where appropriate)					
The patient has FIGO Stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer					
The patient has previously untreated advanced (FIGO Stage IIIB or IIIC) epithelial ovarian, fallopian tube, or primary peritoneal cancer					
	ery is inappropriate				
or					
		g			
and  Bevacizumab to be administered a	It a maximum dose of 15 mg/kg every three weeks				
and 18 weeks concurrent treatment wit					
To weeks concurrent treatment with	п спетношетару із ріанней				
Renewal — advanced or metastatic ovarian car	ncer				
Current approval Number (if known):					
Applications from any relevant practitioner. Approx <b>Prerequisites</b> (tick box where appropriate)	als valid for 4 months.				
There is no evidence of disease progress	sion				
Initial application — Recurrent Respiratory Papillomatosis Applications from any relevant practitioner. Approvals valid for 12 months.  Prerequisites(tick boxes where appropriate)					
relequisites (tick boxes where appropriate)					
Maximum of 6 doses					
The patient has recurrent respiratory papillomatosis and					
The treatment is for intra-lesional a	administration				
Renewal — Recurrent Respiratory Papillomatosis					
Current approval Number (if known):					
Applications from any relevant practitioner. Approvals valid for 12 months.  Prerequisites(tick boxes where appropriate)					
Maximum of 6 doses					
and					
The treatment is for intra-lesional a					
There has been a reduction in surgical treatments or disease regrowth as a result of treatment					

I confirm the above details are correct and that in signing this form I understand I may be audited.

Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 3 Form SA2453 December 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:		
Reg No:	First Names:	First Names:		
Name:	Surname:	Surname:		
Address:	DOB:	Address:		
	Address:			
Fax Number:		Fax Number:		
Bevacizumab - continued				
Initial application — Ocular Conditions Applications from any relevant practitioner. Approvals valid without further renewal unless notified.  Prerequisites(tick boxes where appropriate)				
Ocular neovascularisation				
Exudative ocular angiopathy				

I confirm the above details are correct and that in signing this form I understand I may be audited.